Company curacle co.,ltd.

Equities

A365270

KR7365270008

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
15,510 ^KRW	-4.90%		-13.35%	+33.36%

2023	Curacle Co., Ltd. announced that it has received KRW 20 billion in funding from a group of investors	CI
2023	Curacle Co., Ltd. announced that it expects to receive KRW 20 billion in funding from a group of investors	CI

Curacle Co Ltd is a Korea-based company primarily engaged in the development of therapeutics for intractable vascular and metabolic diseases. The Company researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Companyâs drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers.

KRW in Million	2022	Weight	2023	Weight	Delta
Medicine and Pharmaceutical Research and Development 100.0 %	3,583	100.0 %	10,294	100.0 %	+187.32%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	3,583	100.0 %	10,294	100.0 %	+187.32%

Managers	Title	Age	Since
Kwang-Rak Park CEO	Chief Executive Officer	-	-
Myung-Hwa Kim CEO	Chief Executive Officer	-	-

Members of the board	Title	Age	Since
Myung-Hwa Kim CEO	Chief Executive Officer	-	-
Kwang-Rak Park CEO	Chief Executive Officer	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	13,855,342	9,114,737 ( 65.79 %)	0	65.79 %

Name	Equities	%	Valuation
Curacle Co. Esoa 20.66 %	2,862,827	20.66 %	37 M ₩
Yeong-Geun Kwon 13.06 %	1,809,047	13.06 %	24 M ₩
Tae-yoon Kim 3.399 %	470,880	3.399 %	6 M ₩
In-gyu Lee 3.257 %	451,260	3.257 %	6 M ₩
Kwang-Rak Park 3.073 %	425,800	3.073 %	6 M ₩
Deok-su Jang 2.480 %	343,605	2.480 %	4 M ₩
Honest Ventures Corp. 2.195 %	304,136	2.195 %	4 M ₩
Myung-Hwa Kim 1.554 %	215,357	1.554 %	3 M ₩
Hyun-jung Kwak 0.3609 %	50,000	0.3609 %	654 782 ₩
Young-myung Kim 0.2887 %	40,000	0.2887 %	523 826 ₩

Curacle Co., Ltd.

#608~611 Business growth support center

13449, Seongnam-si

http://www.curacle.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CURACLE CO.,LTD.	+33.36%	166M
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-12.77%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-6.50%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.53B

Bio Therapeutic Drugs